A detailed history of Ronald Blue Trust, Inc. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 72 shares of DNLI stock, worth $1,933. This represents 0.0% of its overall portfolio holdings.

Number of Shares
72
Previous 82 12.2%
Holding current value
$1,933
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

SELL
$20.96 - $31.05 $209 - $310
-10 Reduced 12.2%
72 $2,000
Q2 2024

Jul 18, 2024

BUY
$14.96 - $23.22 $1,226 - $1,904
82 New
82 $1,000
Q2 2023

Jul 14, 2023

BUY
$23.37 - $32.96 $186 - $263
8 Added 114.29%
15 $0
Q1 2023

Apr 17, 2023

SELL
$21.91 - $32.67 $21 - $32
-1 Reduced 12.5%
7 $0
Q4 2022

Jan 17, 2023

BUY
$26.28 - $33.92 $52 - $67
2 Added 33.33%
8 $0
Q3 2022

Oct 21, 2022

BUY
$25.97 - $38.53 $155 - $231
6 New
6 $0

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.6B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Ronald Blue Trust, Inc. Portfolio

Follow Ronald Blue Trust, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ronald Blue Trust, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ronald Blue Trust, Inc. with notifications on news.